- United States
- Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
-
X (Twitter) -
LinkedIn -
Pinterest -
Copy link